warfarin and Osteoporosis--Postmenopausal

warfarin has been researched along with Osteoporosis--Postmenopausal* in 4 studies

Reviews

1 review(s) available for warfarin and Osteoporosis--Postmenopausal

ArticleYear
Warfarin use and fracture risk.
    Nutrition reviews, 2000, Volume: 58, Issue:1

    Two recent studies examined the association between chronic use of warfarin, a vitamin K antagonist, and fracture rate among older women. Whereas one study reported no association, the other reported a significantly higher risk for vertebral and rib fractures among warfarin users compared with nonusers. The effect of vitamin K antagonists on age-related bone loss continues to be controversial.

    Topics: Animals; Anticoagulants; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Vitamin K; Warfarin; Women's Health

2000

Trials

1 trial(s) available for warfarin and Osteoporosis--Postmenopausal

ArticleYear
Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2013, Volume: 20, Issue:3

    Warfarin is an anticoagulant with a narrow therapeutic index that is involved in a number of drug-drug interactions.. This study evaluates the potential effect of odanacatib (a cathepsin K inhibitor in development for the treatment of osteoporosis) on the pharmacokinetics and pharmacodynamics of warfarin.. In a randomized, open-label, two-period fixed-sequence design, 13 healthy, postmenopausal female subjects received two different treatments (Treatment A: a single dose of 30 mg warfarin; Treatment B: 3 once-weekly doses of 50 mg odanacatib with 30 mg warfarin co-administered with the last dose). Warfarin R(+) and S(-) enantiomer concentrations and prothrombin time were measured at pre-dose and at specified time points over 168 hours in each treatment period. Statistical analysis was performed using linear mixed effects model.. Odanacatib was generally well tolerated when co-administered with warfarin in this study. The GMRs (95% confidence intervals [CI]) for plasma AUC0-∞ of warfarin+odanacatib/warfarin alone were 0.99 (0.94, 1.03) for warfarin R(+) and 1.00 (0.97, 1.03) for warfarin S(-), consistent with a lack of interaction between odanacatib and warfarin; results for Cmax, Tmax, and terminal t½ provided also demonstrated no interaction. The GMR (warfarin + odancacatib/warfarin alone) and 95% CI for the statistical comparison of INR AUC(0-168 hr) was 1.01 (0.98, 1.04).. The single dose pharmacokinetics and pharmacodynamics of orally administered warfarin were not meaningfully affected by multiple dose administration of odanacatib, indicating that odanacatib is not a clinically important inhibitor of CYPs 2C9, 3A4, 2C19, or 1A2.

    Topics: Aged; Anticoagulants; Biphenyl Compounds; Cathepsin K; Drug Interactions; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Warfarin

2013

Other Studies

2 other study(ies) available for warfarin and Osteoporosis--Postmenopausal

ArticleYear
Acute subdural hematoma following halo pin tightening in a patient with bilateral vertebral artery dissection.
    Neuro-Chirurgie, 2012, Volume: 58, Issue:6

    We report the first case of acute subdural hematoma (SDH) developing after tightening the halo of an osteoporotic 61-year-old woman on warfarin therapy for bilateral traumatic vertebral artery dissection. We discuss literature relevant to this case with an emphasis on identifying warning signs, including recurrent pin loosening, especially in patients with compromised bone structure and high risk of bleeding. Our 61-year-old patient presented to neurosurgery clinic for a 2-month follow-up of a type-III odontoid fracture sustained in a motor vehicle accident. The patient had repeatedly loosened halo pins, and shortly after the pins were tightened, the patient had a syncopal event and struck her head. An emergent computed tomography scan revealed acute SDH requiring emergent craniotomy and evacuation. SDH following pin penetration in a patient with bilateral vertebral artery dissection, osteoporosis, and anticoagulation has not been reported as a complication of the use of the halo vest for stabilization of the cervical spine. The risk of this serious complication can be minimized by giving special consideration to patients with comorbidities and by repositioning problematic pins. This case demonstrates the importance of special attention to bone strength, bleeding risk, and recurrent minor complaints with use of the halo vest.

    Topics: Accidental Falls; Accidents, Traffic; Anticoagulants; Bone Nails; Craniocerebral Trauma; Craniotomy; Device Removal; Equipment Failure; Female; Hematoma, Subdural, Acute; Hemorrhagic Disorders; Humans; Immobilization; Middle Aged; Odontoid Process; Osteoporosis, Postmenopausal; Risk Factors; Spinal Fractures; Syncope; Tomography, X-Ray Computed; Vertebral Artery Dissection; Warfarin

2012
Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group.
    Annals of internal medicine, 1998, May-15, Volume: 128, Issue:10

    Vitamin K deficiency may be associated with osteoporosis.. To assess the effects of warfarin on bone.. Prospective observational study.. Four centers in the United States.. 6201 elderly, postmenopausal women.. Self-reported warfarin use, bone mineral density at the hip and the heel, hip bone loss over 2 years, and fractures during 3.5 years of follow-up. Analyses were adjusted for baseline differences, age, weight, and estrogen use.. Compared with warfarin nonusers (n = 6052), warfarin users (n = 149) more frequently had poor health, involuntary weight loss, nonthiazide diuretic use, and frailty but had similar bone mineral density at the hip (difference, 1.6% [95% CI, -0.7% to 4.1%]) and heel (difference, 2.1% [CI, -1.6% to 5.6%]). Users and nonusers had similar rates of bone loss (1.1% and 0.8%; P = 0.18) and fractures (relative hazard, 1.0 [CI, 0.60 to 1.71).. In this population, warfarin use did not decrease bone mineral density or increase fracture rates.

    Topics: Aged; Anticoagulants; Bone Density; Female; Follow-Up Studies; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Risk Factors; Warfarin

1998
chemdatabank.com